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INTRODUCTION 
 
 TB  has existed for millennium and remains a major global health 
problem.  TB is one of  the  top 10 causes of death worldwide1. With India 
leading in percentage of TB affected people. 
             
 Malnutrition and tuberculosis are synergistically associated with each 
other. Infection with bacilli does not necessarily lead to active disease as the 
immune response of most individual can successfully contain the infection. 
           
 Action TB is acute inflammatory condition associated with increased 
generation of free radicals that have destructive effect on serum lipids (by 
means of lipid peroxidation)  and also contribute to immune suppression. 
 
 Lipid are important constituent that determine nutritional status and 
the same time participate in immune function. Cholesterol constitute 30% of 
lipid content of plasma membrane and affects its fluidity. Phagocytic cells 
like macrophages require cholesterol for cell motility, exocytosis and 
endocytosis.  Hypocholesterolemic  patients had significantly lower levels 
of lymphocytes, T-cells, helper T-cells, CD8+ cells than hyper-
cholesterolemic people. 
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 It is well established that changes in serum protein occur in response 
to both acute and chronic infection. In pulmonary TB  biochemical 
abnormality such as low serum albumin, increased bilirubin and ALP are 
common. Though hypoalbuminemia is not of diagnostic value, they do 
indicate the severity of infection. With albumin level decrease as the 
severity of disease increases. 
                  
 Hypoalbuminemia and hypocholesterolemia have shown to improve 
with treatment and correlate  well  with recovery from the infection. 
 
  
Aims and objectives 
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AIMS AND OBJECTIVES 
 
 To study the prevalence of  hypoalbuminemia and 
hypocholesterolemia in newly diagnosed pulmonary tuberculosis 
patients 
 
  
Review of literature 
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REVIEW OF LITERATURE 
 
 Tuberculosis has existed for a millennium. It is top 10 cause of death 
worldwide. An estimate of 1.4 million deaths worldwide due to TB and an 
estimate of 0.4 million death in TB patients with HIV. There has been 10.4 
million new TB case in which 1.2 million been in HIV infected people . 5.9 
million men, 3.5 million women and 1 million children1,2. Male to female 
ratio is 1.6:1.   
  
 Prevalence of TB is more among those living in overcrowded place, 
those who are malnourished and homeless. Its incidence has increased 
among HIV-positive individuals. In addition to high prevalence among HIV 
infected people, drug resistance is posing a major problem in disease control 
and treatment. The various genus of the mycobacteria which cause infection 
possess virulence factors like ESAT-6 and CFP-10.   
 
 Infection in persons with normal immune response leads on to 
granuloma formation. 
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Prevalence of TB in INDIA1 
 Mycobacterium tuberculosis had emerged about 70,000 years ago in 
Africa. Disease mostly affects the lungs though other organs can be 
involved in one third of cases5. Disease is fatal in 50 to 60% of patients in 5 
years time if untreated. Transmission is by spread by droplet nuclei from 
infected person6,7.  
 
 Tuberculosis  is  caused  by  any  one  of  three  mycobacterial 
pathogens  that  are  part  of  the  M.  tuberculosis  complex: M.  
tuberculosis,  Mycobacterium  bovis,  and  Mycobacterium africanum8,9. 
The other members of  the M. tuberculosis complex are:  Mycobacterium  
microti,  Mycobacterium  pinnipedii,  and Mycobacterium  caprae,  which  
only  rarely  cause  disease  in humans10. 
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 Mycobacterium  tuberculosis  is  a  rod-shaped,  non-spore-forming,  
thin  aerobic  bacterium  measuring  0.5 micro m  by  3 micro m. In  
addition  to  being  acid  fast,  the  mycobacterium  are  primarily  
intracellular  pathogens,  are  obligate aerobes,  and,  in  the  presence  of  a  
normal  immune response, induce  a  granulomatous  response  in  tissue. 
 
RISK FACTORS FOR ACTIVE TUBERCULOSIS IN PERSONS 
INFECTED WITH TUBERCLE BACILLI 
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PATHOGENESIS 
 Inhalation of the tubercle bacilli through airborne droplet infection 
reaches the aveoli. There they are engulfed by macrophages. Those who 
escape this immune response lead on to infection witth hematogenous and 
lymphatic spread, before the development of effective immune response. 
 
 This stage , primary tuberculosis , is clinically and radiologically 
silent in most of the patients (usually). But in those with inadequate immune 
response, to contain this infection go on to develop progressive primary 
tuberculosis. Persons with intact T-cell, cell mediated immunity limit the 
multplication of TB bacilli by granuloma formation, thus preventing the 
spread. This latent tuberculous infection may reactivate aprox 6% of 
individual when host defences are impaired, leading on to active infection. 
There is no clinical feature that can differentiate primary from latent 
infection, though it is believed that 90% of TB in adukts is due to activation 
of latent infection. 
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 Consequences  of  exposure  to  an  infectious  source  case  of  
tuberculosis  depending  on  the  status  of  immunity.  Exposure  to  a  
patient with  infectious  tuberculosis  causes  tuberculous  infection  in  
approximately  30%  of  those  exposed.  Of  those  who  are  infected,  3%  
to  10%  develop  tuberculosis  within  1  year  of  their  becoming  infected.  
Beyond  1  year,  an  additional  3%  to  5%  develop  tuberculosis  during  
the  remainder  of  their  lifetimes3,11. 
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CLINICAL MANIFESTATION: 
Pulmonary TB 
Pulmonary TB is  categorized  as primary  or post-primary (adult-
type, secondary). Adult  pulmonary  TB  is due to recent  infection (either 
primary infection or re-infection) and not from reactivation. 
 
Primary Disease:  
 Primary pulmonary TB occurs  after initial infection with tubercle 
bacilli. Infection may be asymptomatic or may present with  fever and  
occasional  pleuritic chest  pain.  In areas of  high TB transmission, this 
form of disease mostly seen in children. Since most inspired air is 
distributed to the middle and lower lung zones, these regions are commonly 
affected in primary TB7.  
 
 The lesion after initial infection called Ghon focus is usually 
peripheral and accompanied by transient hilar or paratracheal 
lymphadenopathy, which may or may not be visible on chest X-ray. Some 
develop erythema nodosum or phlyctenular  conjunctivitis.  In the majority 
of infected cases, the  lesion  heals spontaneously evident only as residual 
calcified nodule. Pleural reaction in sub pleural infection is common. The 
Ghon  focus,  with  or without overlying  pleural reaction,  thickening, and 
regional lymphadenopathy, is known as  Ghon complex 
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 In young  children  with  immature cell mediated immunity and in 
those   with impaired  immunity due to malnourishment or HIV infection, 
primary pulmonary TB will progress rapidly. 
 
 Primary TB may present as pleural effusion in two third of cases due 
spread of TB bacilli to pleural space from sub pleural focus. Enlarged lymph 
node may compress the bronchi to cause wheeze by partial obstruction, or   
distal collapse with total obstruction. Rupture of node in bronchi lead on to 
pneumonia. Bronchiectasis may develop in any lobe or segment as a result 
of progressive caseating pneumonia. 
 
The primary site may enlarge rapidly in severe cases where its central 
portion undergoes necrosis resulting in cavity formation (progressive 
primary TB). In young children hilar or paratracheal lymphadenopathy 
occur due to  spread of bacilli from lung parenchyma to lymphatic vessels. 
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 Frontal  chest  radiograph  in  a  young adult  shows  superior  
segment  right  lower  lobe  consolidation  associated with  right  hilar  
lymphadenopathy  (arrow)  due  to  primary  Mycobacterium tuberculosis  
infection.  Mild  right  paratracheal  lymph  node  enlargement (arrowhead)  
is  also  visible. 
 
 Disseminated or miliary spread of primary infection can occur to 
other organs in the absence of sufficient acquired immune response. TB 
meningitis is particular concern in children and HIV infected. 
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POSTPRIMARY DISEASE : Adult type 
 Known as reactivation  or secondary TB, post-primary TB is  most 
accurately termed adult-type TB  as it may result from endogenous 
reactivation of distant latent TB infection or  from primary  infection or re-
infection. Since high mean oxygen tension is present( which favours 
mycobacterium growth) in apical and posterior segments of the upper lobes 
compared with that of lower zones, lesion is most commonly seen in this 
region.. The superior segments of the lower lobes are also frequently 
involved. 
 
 The lung parenchymal involvement may vary from small infiltrate to 
cavitation. In cavitation the liquefied necrotic contents may discharge into 
the airways and undergo bronchogenic spread, resulting in satellite lesions 
within the lungs that may result in cavity formation. Massive involvement 
of pulmonary segments or lobes, will result in caseating pneumonia.  
 
 One third of non treated patient succumb to infection in few months 
known galloping lesion others might go in for cure or chronic progressive 
debilitating illness (“consumption” or  phthisis). These may undergo fibrosis 
and may calcify, but cavities may persist in other parts. Persons with such 
chronic diseases will spread tubercle bacilli for long time. 
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 Usually patients present with fever with evening rise of temperature, 
loss of weight, fatigue, chronic cough which may initially be non productive 
later on becomes muco-purulent with or without hemoptysis. Hemoptysis 
may develop in 20 to 30 percent, massive amount may be due to rupture of 
blood vessel.  
 
 Extensive lung parenchymal involvement will cause dyspnea and 
rarely may lead on to ARDS. On auscultation patient has inspiratory rales, 
particularly after coughing. Patient may have anemia, clubbing and 
haematology wise leukocytosis, thrombocytosis and elevated ESR. C-
reactive protein may be elevated. Hyponatremia may occur due SIADH.  
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EXTRAPUMONARY TB: 
 In descending order of frequency, the extrapulmonary sites most 
commonly involved are the lymph nodes, pleura, genitourinary tract, bones 
and joints, meninges, peritoneum, and pericardium. 
 
Lymph node  
 It is most common form of extra pulmonary TB in both HIV infected 
and non HIV infected patients. Incidence is more in children and HIV 
positive persons. Posterior cervical and supraclavicular nodes are more 
commonly involved. They present usually as discrete non-tender node 
which later coalesce and get matted, later on leading to fistula formation. 
                  
 Diagnosis is by fine needle aspiration or by excision biopsy. Smear is 
positive for AFB or culture is positive in 80% of patients13. Histopathalogic 
examination shows granulomatous caseating lesion. HIV seropositive 
persons have high load of AFB bacilli in both smear and culture, in these 
patients granuloma is poorly formed or absent14. 
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 Corticosteroid  treatment  has  been  used  to  shrink  intra-thoracic  
nodes  and  relieve  bronchial  obstruction,  primarily in  children. Although  
rare,  upper  airway  obstruction  may  result from  cervical  node  
enlargement.  Both  chylous  pleural  effusion  and  ascites  have  resulted  
from  intra-thoracic  or  abdominal  node  involvement  with  obstruction  of  
retroperitoneal lymphatics  or  the  thoracic  duct. 
 
Skeletal Tuberculosis: 
 It accounts for 10% of extra pulmonary tuberculosis. Spine 
involvement upto 50%, knee and hip upto 15%, other bone and joint upto 15 
to 20%17. Spine it affects 2 or more adjacent vertebral bodies. Upper 
thoracic spine is more involved in children compared to lower thoracic and 
lumbar spine in adults. 
 
 Pathogenesis is reactivation of hematogenous foci from initial 
bacillemia or spread from adjacent paravertebral lymph nodes. Evidence of 
either previous or current pulmonary TB is found in approx half of the 
patients reported. 
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 Spine involvement present as paraparesis either due to large abscess 
or tuberculoma or caries spine. Large abscess need urgent surgical drainage. 
Advanced disease lead on to spine deformity inform of Gibbus. 
   
CT and MRI imaging shows characteristic bony lesion. Confirmation 
require synovial fluid aspiration and staining and culture. Synovial biopsy 
and tissue culture may also be required. Evidence of granulomatous 
inflammation do support the diagnosis. 
 
 
 
 Saggital T2 weighted and contrast enhanced T 1 weighted images 
shows anterior paraspinous abscesses typical of subligamental spread. 
Relative sparing of intervertebral  disc space, typical of granulomatous 
infection.  
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 Surgical intervention is usually not required16. Treatment with ATT 
with prolonged period of 6 to 9 month needed as follow up of 
bacteriological clearance is difficult15.  
 
 
Tuberculous  granuloma  with caseation, lymphocytes,  epitheloid  cells 
and Langhans gaint  cells 
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Genitourinary TB: 
 Seeding of kidney occurs during initial infection and bacillemia. In 
90% bilateral kidney is affected18. Genital TB may be associated with renal 
involvement or by a hematogenous spread without renal involvement in 
11%. 
         
         Symptoms include pyuria, hematuria, flank pain, and infertility in 
women and men present as scrotal swelling19. Confirmation is by urine AFB 
and culture of morning first voided urine ( 3 samples) . Isolated genital 
involvement requires biopsy for confirmation and to rule out other cause. 
 
Pleural TB: 
 20 % of extra pulmonary case. Collection of fluid reflect spread of 
bacilli leading on to hypersensitivity reaction to TB bacillus antigen in 
presence of cell mediated immunity20. It may resolve spontaneously even 
without treatment.  
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 Pleural fluid analysis shows >50% of protein that of serum, normal or 
low glucose, ph=7.3 and TC of 100 to 5000 cells mostly lymphocytes21. 
AFB is rarely seen in smear and culture. ADA, lysozyme and interferon 
gamma can be tested. Needle biopsy of pleura may be required which is 
highly specific and sensitive. 
  
 Another form is due to rupture of cavity in pleural space leading onto 
empyema formation. Bronchopleural fistula also may occur. Pleural fluid 
AFB is strongly positive along with culture. It contains cholesterol which 
may mimic chylous effusion hence called pseudo chylous effusion.  
 
 Treatment with ATT and glucocorticoids as a adjuvant. Surgical 
drainage is required may be for long period of time. 
 
Central Nervous system: 
 It accounts for 5 % of extra pulmonary TB.  Incidence is mor 
common among children and HIV seropositive individual. Infection may 
occur by hematogenous spread from primary or post primary infection or 
also due to rupture of subependymal tubercle into subarachnoid space22. It 
evolves over 1-2 weeks, presenting as fever, malaise, headache, seizures and 
neck stiffness. Most of them have old pulmonary healed lesion or miliary 
pattern on chest X-Ray. 
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 CSF analysis shows high leukocyte count 100 to 1000cells/microL23, 
with predominant lymphocytes, with high protein of 100 to 800 mg/ dl and 
low sugar. AFB is not frequently seen but culture turn out to be positive in 
80% of cases. Gene xpert is preferred initial investigation and has 80% 
sensitivity. Though there is response to treatment some25% of patients have 
neurological sequelae. If untreated it has high mortality. 
 
Gastrointestinal TB: 
 It is uncommon of the extra pulmonary TB. TB peritonitis occurs due 
to rupture of lymph node or due to spread from nearby organ. Most common 
site of involvement is terminal ileum and caecum24. Confirmation mostly 
needs tissue biopsy. Spread occurs due to hematogenous seeding, 
swallowing of sputum and drinking of infected milk (bovine). 
 
PERICARDIAL TB: 
 Direct  extension  of an  adjacent  focus  of  disease  from  the  lung  
parenchyma, pleura,  or  tracheobronchial  lymph  nodes  into  the  
pericardium. Also can occur by initial bacillemia, manifesting after period 
of quiescence. It  is  likely  that  hypersensitivity  plays  a role  in  producing  
the  intense  inflammatory  response  and abundant  effusion  in  the  
pericardium. Most  instances  the  fluid  accumulates  slowly,  the  
22 
 
pericardium  can  expand  to  accommodate  large  volumes  (2  to  4  L) 
with  little  apparent  hemodynamic  compromise. 
 
 Tubercle  bacilli  have  been  identified  in  pericardial  fluid  in  
approximately  25%  to  30%  of cases  (smear  and  culture  
combined)25.Biopsy  of  the  pericardium  with  both  histological  and  
bacteriological  evaluation is more specific and sensitive3. 
 
 Constriction occurs with chronic infection of 6 months. Fibrosis cause 
fusion of visceral and parietal pleura leading on to hemodynamic 
compromise. Hence anti-tuberculous treatment should be started early as the 
diagnosis is confirmed or there is stony suspicion of TB. 
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DISSEMINATED or MILIARY TB: 
 The  term  miliary  is  derived  from  the  similarity  of  the  lesions to  
millet  seeds.  Grossly,  these  lesions  are  1-  to  2-mm  yellowish  nodules  
that  on  histological  examination  are  granulomas. In adults it may occur 
as reactivation of old foci or recent infection, in children mostly due to 
primary infection. 
 
 Radiographic abnormality occurs in 70-90%. Combinations  of  
bronchoalveolar  lavage  and  transbronchial  biopsy has high  yield26. Most 
potential  sites  for biopsy  are liver  and  bone  marrow,  which is diagnostic 
of  showing  granulomas  (70%  to  80%)27. 25%  to  40% provide  
bacteriologic  confirmation;  urine  cultures are positive  in  25%  of 
patients28. 
 
HIV –associated TB 
 It is responsible for an estimated 24% mortality amoung HIV infected 
people, being the most common infection in this group of individuals 
worldwide. The annual risk of developing active TB in HIV infected 
persons with TST positive is about 3-14%. Unlike the general population 
new infection of TB in these persons lead on to active infection in weeks 
than in months or years, like in normal person.  
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 At early stages when  CD4 cells are not that much reduced TB 
infection is most commonly pulmonary, with upper lobe cavitation  with 
significant effusion or lymph node enlargement. Though in later stages with 
reduced cell count, extra-pulmonary sites are more commonly affected, with 
pulmonary type showing atypical finding of lower lobe infiltrates, miliary 
distribution, effusion and lymphadenopathy. Infection does not lead on to 
classical granuloma formation with impaired cell mediated immunity. 
 
 Diagnosis is difficult in HIV infected TB patient in view of smear 
negativity and atypical radiological features. Sputum culture are gold 
standard test, Gene-xpert should be routinely done and is also the preferred 
first line investigation. 
 
 Treatment: several studies have shown good response rate in 
concomitant use of ATT and ART in HIV positive TB patients and also has 
reduced the mortality in these patients. 
          
  
25 
 
 
 
 
 ATT is started first followed by initiation or continuation of ART 
within 2 weeks of ATT initiation. ART is indicated for HIV positive TB 
patients at any CD4 count. ART is to be initiated within 2 weeks of ATT at 
CD4 count of < 50 cells. ART should be a combination of two drugs 
nucleoside reverse transcriptase inhibitors and a nonnucleoside reverse 
transcriptase inhibitors. Rifampicin should not be combined with protease 
inhibitors, since rifampicin is a potent inducer of cytochrome P450 enzyme 
system. 
 
COMPLICATION OF TB INFECTION 
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DIAGNOSIS  
1. Sputum smear microscopy (for AFB) 
2. Culture 
3. Rapid molecular diagnostic testing 
a. Line probe assay 
b. Cartridge Based Nucleic acid amplification test ( CBNAAT ) 
the GeneXpert system. 
4. Radiography  
5. Tuberculin skin testing  
 
 Cartridge Based Nucleic Acid Amplification (CBNAAT ) MTB/Rif 
testing using GeneXpert system. 
 Line probe assay for MTB complex and detection of RIF & INH 
resistance 
 WHO recommends the use of XpertMTB/RIF as the initial diagnostic 
test rather than microscopy ,culture and DST. 
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Auramine fluorochrome stain of sputum smear 
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DIAGNOSTIC METHODS IN TUBERCULOSIS 
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Tuberculin skin test: 
 It is of limited value due to low sensitivity and specificity. It is 
usually used to diagnose latent tuberculosis infection. It is to antigenic 
response of T cells in skin. A standard tuberculin test involves 
intracutaneous injection of 0.1ml which contains 5 tuberculin units. The test 
is read at 48-72hrs after injection, but can be read even upto 1 week30 , a 
correctly placed injection causes well-demarcated wheal of 6-10mm in 
diameter.  
 
 A reaction of more than 10mm is considered positive indicative of 
infection. The size of induration is important, than the amount of 
erythema(not taken into account).  
 
 A reaction of even 5mm is considered positive  in HIV infected 
persons and in children in contact with smear positive tuberculosis and 
indicates tuberculous infection. Tuberculin  reactivity  is decreased in 
patients on corticosteroids and immunosuppressive drugs. A minimum dose 
of prednisone of 15 to 20 mg or a equivalent of another preparation, daily 
for 2 to 3 weeks31. Malnutrition and advancing age32  diminish tuberculin 
reactivity. 
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 It cannot differentiate between latent TB infection and active 
infection. False positive result is seen in BCG vaccination and in those with 
non mycobacterial infection. False negative in severe infection and in 
immunocomprimised individual 
 
SIGNIFICANT TUBERCULIN TEST 
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INF-gamma release assay: 
 Two in vitro assays that measure T cell release of  IFN-γ  in  response  
to  stimulation  with  the  highly  TB-specific antigens ESAT-6 and CFP-10 
are available29. It is useful in population with low prevalence of TB and 
HIV. It is reaction of circulating memory T cells. Because of high cost 
WHO has recommended not to replace TST by IGRA in low and middle 
income countries. Two type of test is used currently , the QuantiFERON-TB 
test and T-SPOT.TB test3. T-SPOT.TB test is not affected by CD4 T-cell 
depletion33. Pai and colleagues have conducted study in India in 216 nursing 
and medical students with QFT-GIT test34. 
32 
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ANTI-TUBERCULOUS DRUGS 
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TREATMENT REGIMEN 
 
TREATMENT OF NEWLY DIAGNOSED AND PREVIOUSLY 
TREATED TB CASES 
 
Type of TB cases Treatment regimen in IP 
Treatment regimen in 
CP 
NEW (2) HRZE (4) HRE 
PREVIOUSLY 
TREATED 
( 2)  HRZES + (1) 
HRZE (5) HRE 
 
H- Isoniazid,  R-Rifampicin, Z-Pyrizinamide, E-Ethambutol,  
S-Sterptomycin inj. 
 
 Until now RNTCP had adopted thrice weekly guidelines for 
tuberculosis treatment. The programme is now introducing daily regimen 
treatment of drug sensitive tuberculosis in pediatric and in HIV patients, and 
also all TB patients in 104 districts initially4. Rast of the country will follow 
daily regimen until it is scaled up to daily regimen in entire country4. In 
daily regimen fixed dose combination of drug will be issued daily in 
appropriate weight bands. 
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The continuation phase in both New and Previously Treated Cases may be 
extended by 12 – 24 weeks in certain forms of TB like 
1. CNS TB 
2. Skeletal TB 
3. Disseminated TB 
Based on clinical decision by the treating physician. 
 
MDR/RR-TB cases 
 
Treatment regimen 
in IP 
Treatment regimen 
in CP 
Rifampicin resistant / 
INH sensitive or 
unknown 
Km, Lfx, Eto, Cs, Z, 
E, H (6-9) 
(18) Lfx, Eto, Cs,  
E, H 
MDR TB KM, Lfx, Eto, Cs, Z,  E (6-9) (18) Lfx, Eto, Cs, E 
 
KM- Kanamycin , Lfx- Levofloxacin , E –Ethambutol ,  Eto- Ethionamide, 
Cs- Cycloserine , H – Isoniazid , Z – Pyrazinamide,  
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INH RESISTENCE4 
 High level resistance by liquid culture-omit INH 
 Low level resistance by liquid culture-add high dose INH 
 If  LPA reports INH resistance by KatG mutation – omit INH 
 
If LPA reports INH resistance by INH A mutation – use high dose 
INH. Ethionamide in the treatment regimen will be replaced with PAS 
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TREATMENT OF XDR-TB 
 Treatment regimen in IP Treatment regimen in CP 
XDR 
(6-12) Cm, PAS, Mfx, 
High dose-H, Cfx, Lzd, 
Amx/Clv 
(18)PAS, Mfx, 
High dose H, Cfx, Lzd, 
Amx/Clv 
 
Cm – Capreomycin, PAS – Para-Aminosalicylate Sodium, Mfx – 
Moxifloxacin,  Lzd – Linezolid,  Cfz – Clofazimine, H – Isoniazid,  
Amx/Clv - Amoxyclav 
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Dosage of ATT 
Weight 
category 
Intensive phase 
H R Z E 
75/150/400/275 
Continuation 
phase  H R E 
75/150/275 
Inj.streptomycin 
gm 
25 – 39 kg 2 2 0.5 
40 – 54 kg 3 3 0.75 
55-69 kg 4 4 1 
> 70 kg 5 5 1 
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SIDE EFFECT PROFILE OF FIRST LINE ATT 
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Isoniazid preventive therapy: 
10 mg/kg daily for a period of six months 
 Children <6 years who are close contacts of TB patients 
 For all HIV infected children 
 All TST positive children who are receiving immunosuppressive 
therapy 
 Child born to mother who was diagnosed to have TB in pregnancy  
 
BEDAQUILINE (BDQ) 
 Diarylquinoline specifically targets mycobacterial ATP synthase 
which supplies energy to Mycobacterium. 
 Strong bactericidal 
 High volume of distribution, extensive tissue distribution, highly 
bound to plasma proteins and hepatically metabolised by CYP3A4 
 Has extended half life ,means present in the plasma up to 5.5 months 
post stopping BDQ 
 No cross resistance with first line and second line TB drugs. 
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Criteria : 
1. Adults aged > 18 years having Pulmonary  MDR-TB. 
2. Females should not be pregnant or should be using effective non 
hormone based birth control pills . 
 
Dosage : 
 400 mg a day for 2 weeks,  200 three times a week for 22 weeks    
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ASSESSING RISK FOR DRUG RESISTANCE 
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SERUM PROTEINS AND LIPIDS IN TUBERCULOSIS 
 
             Lipids are important part of immune system. Cholesterol is involved 
in membrane functions like phagocystosis and cell growth. Studies have 
shown that lipids are involved in proliferation cycles that convert 
lymphocytes into cytotoxic cells, enhance macrophage ability to engulf 
mycobacterium, its content in lymphocyte is needed for lymphocyte’s 
cytotoxic action. Cholesterol is needed for release of interferon-gamma and 
TNF-alpha from macrophages that render them efficient killing of  
mycobacterium. 
                
 Various studies have that cholesterol intergral part of cellular 
immunity, low levels of which has destructive effect on lymphocyte and 
macrophage. Not only in tuberculosis lipids are found to be reduced in other 
bacterial infection and sepsis.  
                   
 Though extact mechanism underlying low serum lipids in sepsis and 
severe illness is not known , could be due to interaction of  cytokines and 
toxins with lipids and leading to destruction of lipids by peroxidation. 
Cholesterol and lipoprotein mediate clearance of  lipopolysaccharide 
(produced by bacteria) by detoxification.  
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 During severe infection cytokines produced, causes decrease in the 
level of  cholesterol. Lipoproteins are also involved in clearance of DNA 
and RNA viruses and also in defence against parasite.  
 
 Studies have shown that lipid levels are lower in tuberculosis patients 
compared to their household contact35. Cholesterol supplementation has 
shown faster bacteriological sterilization of sputum compared to those given 
placebo36. Lipids are also reduced in inflammatory conditions. Cytokines 
and toxins produces during infection decrease appetite, resulting in weight 
loss37.  
         
 Cholesterol seems to correlate with severity of infection with lower 
levels associated with more severe radiological destruction of lung 
parenchyma and sputum positivity36,38,41.  
                         
 It is well established that changes in serum protein occur in response 
to both acute and chronic infection. In pulmonary TB  biochemical 
abnormality such as low serum albumin, increased bilirubin and ALP are 
common. Though hypoalbuminemia is not of diagnostic value, they do 
indicate the severity of infection39. With albumin level decrease as the 
severity of disease increases.  
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 Studies have shown significant lower levels of serum proteins and 
lipids in patients with tuberculosis and community acquired pneumonia than 
in contacts and a inverse relationship between radiological extent of 
infection and HDL levels 
            
 Hypoalbuminemia and hypocholesterolemia have shown to improve 
with treatment and correlate well with recovery from the infection.  Hence 
this could be used to asses the severity of the disease and response to 
treatment. Hence the aim of the study is to know the prevalence of 
hypocholestrelemia and hypoalbuminemia in pulmonary tuberculosis 
patients.  
        
 Being a simple non invasive method this could be used to monitor 
patients on ATT during follow up on treatment course. 
  
Materials and methods 
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MATERIALS AND METHODS 
 
SETTING 
 This study was conducted at the Institute of  Internal Medicine, Rajiv  
Gandhi Government General Hospital (RGGGH), Madras Medical College, 
Chennai. 
 
ETHICAL COMMITTEE APPROVAL 
 Obtained 
 
STUDY DURATION 
 This study was conducted over a period of six months. 
 
STUDY POPULATION 
 Patients who were admitted with pulmonary tuberculosis to the 
medical 
 Wards at the Institute of Internal Medicine. 
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SAMPLE SIZE 
 Case  : 50 
 Control  : 50 
 
TYPE OF STUDY 
 Case-Control study 
 
CASE 
Inclusion criteria: 
1) Pulmonary tuberculosis 
2) Age 20 to 50 years 
3) Newly diagnosed  
 
Exclusion criteria: 
1) Patients suffering from liver disease 
2) Pregnant patients 
3) Patients with HIV infection         
4) Patients with terminal  illness. 
5) Any previous anti tuberculous drug treatment 
6) Extrapulmonary Tuberculosis  
  
50 
 
CONTROL 
Inclusion criteria: 
 Age and gender matched healthy contacts or asymptomatic 
individuals with no evidence of tuberculosis based on history and 
clinical examination of 20- 50 years 
 
Exclusion criteria: 
1) Any liver disease 
2) Pregnancy 
3) With HIV infection 
4) With terminal illness. 
5) Any previous anti tuberculous drug treatment 
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DATA COLLECTION AND METHODS 
 On patients who were admitted in RGGGH, Chennai, a case-control 
study on newly diagnosed smear positive pulmonary tuberculosis patient 
(case) and with age and gender matched control with no previous or current 
history of tuberculosis , for period of 6months. Case and control were 
selected according to the inclusion and exclusion criteria. Detail history 
taking and examination will be done. 
 
 In all patients 3 to 4 ml of venous blood will be collected in a sterile 
manner in plain red tube for serum protein estimation. And a fasting early 
morning sample be take for estimation of cholesterol and HDL level. 
Observation and results 
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OBSERVATION & RESULTS 
 
AGE DISTRIBUTION IN CASE AND CONTROL GROUP 
AGE DISTRIBUTION 
GROUP 
Total 
Case Control 
20-30 Years 
Count 12 12 24 
% within group 24.0% 24.0% 24.0% 
31-40 Years 
Count 18 18 36 
% within group 36.0% 36.0% 36.0% 
41-50 Years 
Count 20 20 40 
% within group 40.0% 40.0% 40.0% 
 
Total 
Count 50 50 100 
% within group 100.0% 100.0% 100.0% 
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SEX DISTRIBUTION IN CASE AND CONTROL GROUP 
 
 
 
 
 
 
 
0
5
10
15
20
25
30
35
MALE FEMALE
CASE
CONTROL
SEX CASE CONTROL PERCENT 
Male 30 30 60 
Female 20 20 40 
Total 50 50 100.0 
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COMPARISION OF  LEVELS OF SERUM PROTEIN, ALBUMIN, 
CHOLESTEROL AND HDL IN CASE AND CONTROL 
 
Group N Mean Std. Deviation 
Std. 
Error 
Mean 
t value p value 
AGE 
Case 50 37.46 8.29 1.17 
0.012 0.99 
Control 50 37.44 8.15 1.15 
SERUM 
PROTEIN  
g/dl 
Case 50 5.22 0.73 0.10 
15.484** p<0.001 
Control 50 6.98 0.33 0.05 
ALBUMIN  
mg/dl 
Case 50 2.70 0.42 0.06 
16.998** p<0.001 
Control 50 4.02 0.35 0.05 
CHOLESTEROL 
mg/dl 
Case 50 114.62 22.40 3.17 
13.518** p<0.001 
Control 50 159.40 6.86 0.97 
HDL mg/dl 
Case 50 33.14 10.03 1.42 
15.819** p<0.001 
Control 50 58.34 5.13 0.73 
 
**p<0.001 highly significant 
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COMPARISION OF SERUM PROTEIN AND ALBUMIN     
LEVELS BETWEEN CASE AND CONTROL 
 
SERUM PROTEIN 
g/dl 
Group 
Total 
Case Control 
Abnormal 
Count 47 3 50 
% within group 94.0% 6.0% 50.0% 
Normal 
Count 3 47 50 
% within group 6.0% 94.0% 50.0% 
Total 
Count 50 50 100 
% within group 100.0% 100.0% 100.0% 
 
 
ALBUMIN 
mg/dl 
Group 
Total 
Case Control 
Abnormal 
Count 48 1 49 
% within group 96.0% 2.0% 49.0% 
Normal 
Count 2 49 51 
% within group 4.0% 98.0% 51.0% 
Total 
Count 50 50 100 
% within group 100.0% 100.0% 100.0% 
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MEAN SERUM PROTEIN AND ALBUMIN LEVEL IN CASE AND 
CONTROL 
 
   
5.22
2.7
6.98
4.02
0
1
2
3
4
5
6
7
8
SERUM PROTEIN ALBUMIN
CASE
CONTROL
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COMPARISION OF SERUM CHOLESTEROL AND HDL LEVELS 
BETWEEN CASE AND CONTROL 
CHOLESTEROL 
Group 
Total 
Case Control 
Abnormal 
Count 50 50 100 
% within group 100.0% 100.0% 100.0% 
Total 
Count 50 50 100 
% within group 100.0% 100.0% 100.0% 
 
 
HDL 
Group 
Total 
Case Control 
Abnormal 
Count 46 1 47 
% within group 92.0% 2.0% 47.0% 
Normal 
Count 4 49 53 
% within group 8.0% 98.0% 53.0% 
Total 
Count 50 50 100 
% within group 100.0% 100.0% 100.0% 
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MEAN  SERUM  CHOLESTEROL  AND  HDL  LEVEL  IN  CASE  
AND CONTROL  GROUP 
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AGE DISTRIBUTION OF SPUTUM AFB POSTIVITY IN CASE 
 
AGE 
SPUTUM AFB 
TOTAL 
1+ 2+ 3+ 
20-30 Years 
Count 2 5 5 12 
% within SPUTUM 
AFB 16.7% 25% 35.7% 24.0% 
31-40 Years 
Count 4 7 7 18 
% within SPUTUM 
AFB 33.3% 36.8% 50% 36.0% 
41-50 Years 
Count 8 8 4 20 
% within SPUTUM 
AFB 57.1% 43% 25% 40.0% 
Total 
Count 14 20 16 50 
% within SPUTUM 
AFB 100.0% 100.0% 100.0% 100.0% 
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AGE DISTRIBUTION OF SPUTUM AFBPOSTIVITY IN CASE  
 
 
 
  
0
1
2
3
4
5
6
7
8
9
20-30 31-40 41-50
sputum AFB 1+
sputum AFB 2+
sputum AFB 3+
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CORRELATION OF SERUM PROTEIN AND SPUTUM AFB 
POSTIVITY IN CASE 
 
SERUM  PROTEIN 
SPUTUM  AFB 
Total 
1+ 2+ 3+ 
Abnormal 
Count 11 20 16 47 
% within  Sputum 
AFB 75.0% 100.0% 100.0% 94.0% 
Normal 
Count 3 0 0 3 
% within  Sputum 
AFB 25.0% 0.0% 0.0% 6.0% 
Total 
Count 14 20 16 50 
% within  Sputum 
AFB 100.0% 100.0% 100.0% 100.0% 
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CORRELATION OF SERUM ALBUMIN AND SPUTUM AFB 
POSTIVITY IN CASE 
 
ALBUMIN 
SPUTUM AFB 
Total 
1+ 2+ 3+ 
Abnormal 
Count 12 20 16 48 
% within Sputum 
AFB 83.3% 100.0% 100.0% 96.0% 
Normal 
Count 2 0 0 2 
% within Sputum 
AFB 16.7% 0.0% 0.0% 4.0% 
Total 
Count 14 20 16 50 
% within Sputum 
AFB 100.0% 100.0% 100.0% 100.0% 
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CORRELATION OF SERUM CHOLESTEROL AND SPUTUM AFB  
POSTIVITY IN CASE 
 
CHOLESTEROL 
SPUTUM AFB 
Total 
1+ 2+ 3+ 
Abnormal 
Count 14 20 16 50 
% within  
Sputum AFB 100.0% 100.0% 100.0% 100.0% 
Total 
Count 14 20 16 50 
% within  
Sputum AFB 100.0% 100.0% 100.0% 100.0% 
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CORRELATION OF HDL LEVEL AND SPUTUM AFB POSTIVITY 
IN     CASE 
 
SPUTUM  AFB 
Total 
1+ 2+ 3+ 
HDL 
Abnormal 
Count 10 20 16 46 
% within 
SPUTUM  AFB 66.7% 100.0% 100.0% 92.0% 
 
 
Normal 
Count 4 0 0 4 
% within 
SPUTUM  AFB 33.3% 0.0% 0.0% 8.0% 
Total 
Count 14 20 16 50 
% within 
SPUTUM  AFB 100.0% 100.0% 100.0% 100.0% 
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CORRELATION COEFFICIENT OF LEVELS OF SPUTUM AFB 
AND SERUM LEVELS OF PROTEIN, ALBUMIN, CHOLESTEROL 
AND HDL IN CASE 
 
 SPUTUM AFB 
SERUM PROTEIN g/dl 
Correlation Coefficient -.908** 
Sig. (2-tailed) p<0.0001 
N 50 
ALBUMIN g/dl 
Correlation Coefficient -.934** 
Sig. (2-tailed) p<0.0001 
N 50 
CHOLESTEROL mg/dl 
Correlation Coefficient -.954** 
Sig. (2-tailed) p<0.0001 
N 50 
HDL mg/dl 
Correlation Coefficient -.843** 
Sig. (2-tailed) p<0.0001 
N 50 
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RESULTS 
 
AGE DISTRIBUTION: 
 In our study mean age of case and control is 37.46. In case about 24% 
patients are between age 20 to 30, 36% patients are between  age 31 to 40, 
40% patients are between age 41 to 50. Same as in control group. 
 
SEX DISTRIBUTION: 
 In our study, 60% are males in both case and control group and 40% 
are females in both case and control group. 
 
MEAN SERUM PROTEIN LEVEL IN CASE AND CONTROL: 
 Mean serum protein level in case is 5.22 g/dl and in control is 
6.98g/dl. 
 
MEAN SERUM ALBUMIN LEVEL IN CASE AND CONTROL: 
 Mean serum albumin level in case is 2.7g/dl and in control is 4.02 
g/dl. 
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MEAN SERUM CHOLESTEROL LEVEL IN CASE AND 
CONTROL: 
 Mean serum cholesterol level in case is 114.62 mg/dl and in control is 
159.40 mg/dl. 
 
MEAN SERUM HDL LEVEL IN CASE AND CONTROL: 
 Mean serum HDL level in case is 33.14 mg/dl and in control is 58.34 
mg/dl. 
 
DISTRIBUTION OF SPUTUM AFB IN CASES (AGE WISE): 
 Sputum AFB 1+ is about 16.7% in age group 20-30yrs, 33.3% in age 
group 31-40 yrs, 57.1%  in age group 41-50 yrs. Sputum AFB 2+ is about 
25% in age group 20-30yrs, 36.8% in age group 31-40 yrs, 43% in age 
group 41-50yrs. Sputum AFB 3+ is about 35.7% in age group 20-30yrs, 
50% in age group 31-40 yrs, 25 % in age group 41-50 yrs.  
 
DISTRIBUTION OF SPUTUM AFB IN CASE (SEX WISE): 
 In males sputum AFB 1+ is positive in 8,  2+ in 12 and  3+  in 9. In 
females sputum AFB 1+ is positive in 8,  2+ in 8 and  3+ in 5 . 
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COMPARISION OF SERUM LEVELS OF PROTEIN, ALBUMIN, 
CHOLESTEROL AND HDL BETWEEN CASE AND CONTROL: 
 In our study, we compared the levels of the above said parameters 
between case and control. p value was found to be 0.99 in comparison of 
age distribution between case and control which is insignificant. p value is 
of <0.001 in comparision of serum levels of protein, albumin, cholesterol 
and HDL between case and control group which is highly significant. 
 
CORRELATION OF SERUM LEVELS OF PROTEIN, ALBUMIN, 
CHOLESTEROL AND HDL WITH SPUTUM AFB POSTIVITY IN 
CASE:                    
 In our study, correlation of sputum AFB positivity with above 
mentioned value has shown as the sputum positivity increases the measured 
serum levels of the values decreases, indicating as the bacterial load 
increases the values decrease. p value on individual correlation  of  serum 
levels of protein, albumin, cholesterol and  HDL and sputum positivity ( 
from 1+ to 3+) is highly significant <0.0001 33,12,41. 
  
Discussion 
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DISCUSSION 
 
 In this study 50 patients of newly diagnosed sputum  positive  
pulmonary tuberculosis  diagnosed at RGGGH were selected and their 
serum levels of protein, albumin, cholesterol and HDL was compared with 
50 age and gender matched controls. Case and control were selected as per 
the inclusion and exclusion criteria. They were subjected to detail clinical 
examination. 
 
 p value obtained by this comparison and with correlation of the serum 
protein, albumin cholesterol and HDL levels with sputum positivity in case 
was found to be highly significant. 
 
Sample size: 
 In this case control study, 50 were cases(newly diagnosed pulmonary 
tuberculosis) and 50 control were included. In Ofor. I.B. et al study 16  was 
newly diagnosed TB, 20 on ATT for 3 months, 20 on ATT for 6 months and 
20 were healthy volunteers as control34.  In Laxmikant Chavan33 study 100 
patients of newly diagnosed pulmonary and extrapulmonary TB were 
included.  
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AGE: 
 In this study, mean age was 37.46 years  in case and 37.44 years  in 
control. .In Laxmikant Chavan study mean age of adults less than 40 years 
was 32.71 and mean age above 40 years was 67.57 years. Ofor. I.B  study  
subjects included were of age group 15-60 years.  
 
SEX: 
 In this study, 30 were male and 20 female in both case and control. 
  
Comparision of serum  levels of protein, albumin, cholesterol and HDL 
in case and control.  
 p value was found to be significant in comparison of above mentioned 
variables between case and control. The value did correlate with sputum 
AFB positivity in this study , with p value being significant12,41 . This is 
supported by Laxmikant  Chavan study where the levels of serum proteins 
correlated with severity of infection by sputum AFB and radiological extent 
of the disease.  
          
 
  
Conclusion 
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CONCLUSION 
  
 This study showed that serum levels of protein, albumin, cholesterol 
and HDL was low in case compared to control and that these values were in 
decreasing trend as the sputum positivity increased from 1+ to 4+. 
Indicating that as the bacterial load increases and severity of  infection 
increased these values decreased. Hence they may be play significant role in 
monitoring tuberculosis patients on ATT to look for improvement in these 
serum levels as the bacterial load decreases and sputum becomes negative. 
And to may add a benefit in looking for response to treatment in these 
patients with improvement both clinically and biochemically. 
  
Limitations 
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LIMITATIONS 
 
 Sample size being less in the view of the  load of this disease in our 
country.  
 Extra –pulmonary TB not been included. 
 Long term follow up of these patients to look for improvement in these 
parameters with treatment. 
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Annexures 
PROFORMA 
  
1. Name: 
2. Age/Sex: 
3.IP.No.: 
4.Diagnosis: 
5.Occupation: 
 
COMPLAINTS: 
 
 
PAST HISTORY: 
1. DM/SHT 
2. CLD 
3. TB 
4. HIV 
5. CHRONIC RENAL FAILURE 
6. CAD 
 
PERSONAL HISTORY: 
Alcoholic/ smoker: 
 
VITALS: 
BP: 
PULSE RATE: 
 
  
 EXAMINATION: 
General examination 
 1)  Conscious / Oriented  
 2)  Pallor / Icterus 
 3) Pedal Edema  
 4) Lymphadenopathy 
 
Systemic examination 
Cardiovascular system: 
 
Respiratory system: 
 
Abdomen: 
 
CNS: 
 
INVESTIGATIONS 
 
Total protein: 
 
Albumin: 
 
Globulin: 
 
Lipid profile:    
 
Total cholesterol 
 
HDL  
  
 
INFORMATION SHEET 
 
 We are conducting a study on “A CASE-CONTROL STUDY ON  
SERUM PROTEIN, CHOLESTEROL AND HDL LEVELS IN  
PULMONARY TUBERCULOSIS PATIENTS.” among patients attending 
Rajiv Gandhi Government General Hospital, Chennai and for that your co-
operation to undergo relevant investigations as per need may be valuable to us. 
 
 The purpose of this study is to study the prevalence of hypoalbuminemia 
and  hypocholestrelemia  in pulmonary tuberculosis patients. 
 
 We are selecting certain cases and if you are found eligible, we would 
like to perform extra tests and you will be subjected to a non invasive procedure 
like estimation of serum protein, cholesterol and HDL level which in any way 
do not affect your final report or management. 
 
 The privacy of the patients in the research will be maintained throughout 
the study. In the event of any publication or presentation resulting from the 
research, no personally identifiable information will be shared. 
 
 Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not result 
in any loss of benefits to which you are otherwise entitled. 
 
 The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may aid in 
the management or treatment. 
 
 
 
 
Signature of Investigator    Signature/left thumb  
       impression of Participant 
  
PATIENT CONSENT FORM  
                                    
Study Detail  
 
 
 
 
: 
“A CASE-CONTROL STUDY ON SERUM PROTEIN, 
CHOLESTEROL AND HDL LEVELS IN PULMONARY 
TUBERCULOSIS PATIENTS.” 
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
Patient’s Name :  
Patient’s Age :  
In Patient Number :  
                                                                                                      
 
Study Investigator’s Name                                            Signature/thumb impression                                                          
 
Study Investigator’s Name:                                                                                      
Dr. K.TEENA                                                              Patient’s Name and Address: 
  
a) I confirm that I have understood the purpose of procedure for the above study. I have 
the opportunity to ask question and all my questions and doubts have been answered 
to my complete satisfaction. 
o 
b) I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being affected. o 
c) I understand that sponsor of the clinical study, others working on the sponsor’s 
behalf, the ethical committee and the regulatory authorities will not need my 
permission to look at my health records, both in respect of current study and any 
further research that may be conducted in relation to it, even if I withdraw from the 
study I agree to this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published, unless as required 
under the law. I agree not to restrict the use of any data or results that arise from this 
study. 
o 
d) I agree to take part in the above study and to comply with the instructions given 
during the study and faithfully cooperate with the study team and to immediately 
inform the study staff if I suffer from any deterioration in my health or well being or 
any unexpected or unusual symptoms. 
o 
e) I hereby consent to participate in this study. o 
f) I hereby give permission to undergo detailed clinical examination and relevant 
investigations as required. o 
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MASTER CHART 
                               
CASE 
   
S.No. AGE SEX SPUTUM AFB SERUM PROTEIN g/dl ALBUMIN g/dl CHOLESTEROL mg/dl HDL mg/dl
1 40 M 1+ 6 2.8 140 44
2 35 M  2+ 5 2.5 109 32
3 42 F 2+ 5.5 2.8 110 36
4 24 M 3+ 5 2.5 100 26
5 49 F 1+ 4.5 2.2 80 18
6 25 F 2+ 5.6 2.9 120 35
7 34 F 3+ 4.1 2.3 98 21
8 36 M 1+ 5.9 3.2 143 50
9 44 M 2+ 5.2 2.4 116 38
10 26 M 2+ 5.3 2.5 130 40
11 47 M 1+ 4.1 2.3 78 16
12 38 F 3+ 4.5 2.3 100 22
13 40 M 2+ 5.4 2.6 118 32
14 45 F 1+ 6.4 3.3 136 48
15 33 M 2+ 5.5 2.9 124 36
16 25 M 2+ 5.4 2.8 112 38
17 50 F 2+ 5.2 2.9 108 34
18 21 F 3+ 4.6 2.4 94 28
19 43 M 1+ 6.3 3.1 144 45
20 38 M 2+ 5.2 3.1 108 28
21 48 F 2+ 5.4 2.6 127 38
22 29 F 3+ 5 2.3 86 24
23 35 M 1+ 5 3.4 142 24
24 42 M 2+ 5 2.6 115 24
25 41 F 2+ 5 3 129 24
  
 
 
 
  
S.No. AGE SEX SPUTUM AFB SERUM PROTEIN g/dl ALBUMIN g/dl CHOLESTEROL mg/dl HDL mg/dl
26 25 M 1+ 6.2 3.2 144 45
27 37 M 3+ 4.1 2.3 98 27
28 47 F 1+ 6.2 3.2 137 46
29 25 M 3+ 4.4 2.4 99 29
30 33 F 2+ 5.4 2.7 110 35
31 45 M 1+ 6 3.3 145 47
32 39 M 3+ 4.6 2.3 97 29
33 50 M 3+ 4.7 2.3 100 32
34 29 F 3+ 4.8 2.4 105 31
35 31 F 1+ 6.6 3.7 154 50
36 38 M 2+ 6.7 3.5 156 49
37 42 M 3+ 5 2.3 86 24
38 49 F 3+ 4.1 2.2 78 16
39 37 F 2+ 5.5 2.8 120 40
40 42 F 1+ 6.7 3.6 160 52
41 24 M 2+ 5.4 2.7 118 29
42 49 F 2+ 5.5 2.7 114 35
43 28 F 1+ 6.2 3.1 146 46
44 36 M 3+ 4.3 2.1 80 19
45 29 M 2+ 4 2 78 18
46 31 M 3+ 4.8 2.3 90 30
47 39 M 3+ 4.6 2.3 96 22
48 45 M 2+ 6.7 3.6 158 52
49 46 M 1+ 6.8 3.7 157 51
50 47 M 3+ 4.4 2.4 100 28
  
CONTROL 
 
  
S.No. AGE SEX SPUTUM AFB SERUM PROTEIN g/dl ALBUMIN g/dl CHOLESTEROL mg/dl HDL mg/dl
1 25 M - 6.6 3.6 155 50
2 36 M - 6.7 3.8 155 50
3 31 F - 7.1 4.2 155 50
4 42 F - 7.2 4 155 58
5 26 M - 6.9 4.5 155 49
6 29 M - 6.6 3.5 155 50
7 21 F - 7 3.8 155 60
8 33 F - 7.2 3.9 155 61
9 44 M - 6.9 4.2 155 55
10 35 M - 7.6 3.7 155 59
11 25 F - 7.5 4.4 155 62
12 34 F - 6.7 4.2 155 65
13 38 M - 6.8 4.7 155 67
14 42 M - 7 4.3 155 58
15 39 M - 7.1 4.5 155 60
16 38 F - 7.3 3.7 155 58
17 37 F - 6.9 3.8 155 62
18 30 F - 7.4 4 155 64
19 26 M - 7 4.1 155 52
20 38 M - 6.9 3.9 155 55
21 39 M - 7.2 4.4 155 56
22 47 M - 6.7 4.2 155 62
23 48 F - 6.9 3.8 155 64
24 48 M - 7.1 3.6 155 59
25 49 F - 6.5 3.6 155 55
  
 
 
 
 
 
S.No. AGE SEX SPUTUM AFB SERUM PROTEIN g/dl ALBUMIN g/dl CHOLESTEROL mg/dl HDL mg/dl
26 28 M - 7.8 4.5 165 57
27 25 M - 7.1 4 155 56
28 33 M - 6.7 4.3 160 60
29 48 F - 6.9 3.7 162 66
30 29 F - 7.2 3.8 164 70
31 41 F - 7.1 3.6 180 53
32 45 M - 6.6 4.2 159 56
33 50 M - 6.9 4.7 167 59
34 26 F - 7.8 4.9 154 60
35 49 F - 6.7 4 179 52
36 24 M - 6.9 3.6 154 60
37 47 M - 6.6 3.4 158 64
38 43 F - 7.5 3.8 157 65
39 45 F - 7.4 4.2 174 68
40 41 M - 7.2 4.3 167 56
41 44 M - 6.6 4.5 156 55
42 46 M - 6.7 4.2 161 57
43 50 F - 6.8 4.2 165 62
44 36 M - 7.1 4.1 154 63
45 36 M - 7 3.9 172 57
46 35 M - 6.5 3.7 173 59
47 42 F - 6.5 3.9 165 55
48 40 M - 6.6 3.9 163 50
49 31 M - 7.1 3.7 165 61
50 38 M - 6.7 3.5 166 55
